OTCPK:RKAG.Y

Stock Analysis Report

Executive Summary

RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany.

Snowflake

Fundamentals

Excellent balance sheet with questionable track record.

Risks

  • RHÖN-KLINIKUM has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has RHÖN-KLINIKUM's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.0%

OTCPK:RKAG.Y

0.8%

US Healthcare

1.3%

US Market


1 Year Return

-7.2%

OTCPK:RKAG.Y

-8.2%

US Healthcare

2.0%

US Market

RKAG.Y matched the Healthcare industry (-8.2%) over the past year.

RKAG.Y underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

RKAG.YIndustryMarket
7 Day1.0%0.8%1.3%
30 Day-2.6%-1.5%3.9%
90 Day-16.2%-0.5%3.4%
1 Year-6.5%-7.2%-6.8%-8.2%4.2%2.0%
3 Yearn/a30.2%24.9%47.2%37.6%
5 Yearn/a63.6%53.9%60.5%42.9%

Price Volatility Vs. Market

How volatile is RHÖN-KLINIKUM's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is RHÖN-KLINIKUM undervalued based on future cash flows and its price relative to the stock market?

28.28x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

RHÖN-KLINIKUM's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

RHÖN-KLINIKUM's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

RHÖN-KLINIKUM is overvalued based on earnings compared to the US Healthcare industry average.

RHÖN-KLINIKUM is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

RHÖN-KLINIKUM earnings are not expected to grow next year, we can't assess if its growth is good value.


Price Based on Value of Assets

RHÖN-KLINIKUM is good value based on assets compared to the US Healthcare industry average.


Next Steps

Future Growth

How is RHÖN-KLINIKUM expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

-3.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

RHÖN-KLINIKUM's revenue is expected to grow by 2.4% yearly, however this is not considered high growth (20% yearly).

RHÖN-KLINIKUM's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.

RHÖN-KLINIKUM's revenue growth is positive but not above the United States of America market average.

RHÖN-KLINIKUM's earnings are expected to decrease over the next 1-3 years, this is below the United States of America market average.

RHÖN-KLINIKUM's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if RHÖN-KLINIKUM will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has RHÖN-KLINIKUM performed over the past 5 years?

-73.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

RHÖN-KLINIKUM's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.

RHÖN-KLINIKUM's 1-year earnings growth exceeds its 5-year average (43.3% vs -73%)

RHÖN-KLINIKUM's earnings growth has exceeded the US Healthcare industry average in the past year (43.3% vs 5.6%).


Return on Equity

RHÖN-KLINIKUM has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

RHÖN-KLINIKUM used its assets less efficiently than the US Healthcare industry average last year based on Return on Assets.


Return on Capital Employed

RHÖN-KLINIKUM's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is RHÖN-KLINIKUM's financial position?


Financial Position Analysis

RHÖN-KLINIKUM is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

RHÖN-KLINIKUM's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

RHÖN-KLINIKUM's level of debt (8.7%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has increased over the past 5 years (5.8% vs 8.7% today).

Debt is well covered by operating cash flow (73%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 25.1x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 5.2x debt.


Next Steps

Dividend

What is RHÖN-KLINIKUM's current dividend yield, its reliability and sustainability?

1.23%

Expected Dividend Yield


Dividend Yield and Payments Analysis

RHÖN-KLINIKUM's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.45%).

RHÖN-KLINIKUM's dividend is below the markets top 25% of dividend payers in United States of America (3.67%).

Dividends per share have been volatile in the past 10 years (annual drop of over 20%).

Dividends per share have fallen over the past 10 years.


Current Payout to Shareholders

Dividends paid are well covered by earnings (2.7x coverage).


Future Payout to Shareholders

Dividends after 3 years are expected to be well covered by earnings (2.3x coverage).


Next Steps

Management

What is the CEO of RHÖN-KLINIKUM's salary, the management and board of directors tenure and is there insider trading?

2.6yrs

Average management tenure


CEO

Stephan Holzinger 0

2.6yrs

Tenure

€2,271,000

Compensation

Mr. Stephan Holzinger serves as a Management Consultant at Lenggries. Mr. Holzinger has been Chairman of Management Board at Rhön-Klinikum Aktiengesellschaft since February 1, 2017. He is Chief Executive O ...


CEO Compensation Analysis

Stephan's remuneration is lower than average for companies of similar size in United States of America.

Stephan's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

2.6yrs

Average Tenure

67yo

Average Age

The tenure for the RHÖN-KLINIKUM management team is about average.


Board Age and Tenure

9.3yrs

Average Tenure

The tenure for the RHÖN-KLINIKUM board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Jörg Demmler (67yo)

    Head of Technical Controlling & Environment

    • Tenure: 0yrs
  • Franz Mlynek (67yo)

    Divisional Head of Major Investments

    • Tenure: 0yrs
  • Esther Walter

    Head of Group Press and Public Relations

    • Tenure: 0yrs
  • Stephan Holzinger

    Chairman of Board of Management & CEO

    • Tenure: 2.6yrs
    • Compensation: €2.27m
  • Bernd Griewing

    Chief Medical Officer & Member of Board of Management

    • Tenure: 3.7yrs
    • Compensation: €1.37m
  • Harald Auner

    Head of Group Division

    • Tenure: 0yrs
  • Gunther Karl Weiß (53yo)

    COO & Member of Management Board

    • Tenure: 1.3yrs
    • Compensation: €751.00k
  • Julian Schmitt

    Head of Investor Relations & Treasury

    • Tenure: 0yrs
  • Elke Pfeifer

    Head of Corporate Communications and Marketing

    • Tenure: 0yrs

Board Members

  • Gerhard Ehninger

    Member of Supervisory Board

    • Tenure: 0yrs
    • Compensation: €54.00k
  • Michael Wendl

    Member of Advisory Board

    • Tenure: 0yrs
    • Compensation: €80.00k
  • Brigitte Mohn

    Member of Supervisory Board

    • Tenure: 17.2yrs
    • Compensation: €56.00k
  • Eugen Münch

    Chairman of Supervisory Board

    • Tenure: 14yrs
    • Compensation: €357.00k
  • Frederik Wenz

    Chairman of Advisory Board

    • Tenure: 10.8yrs
  • Georg Milbradt

    Member of Advisory Board

    • Tenure: 0yrs
  • Stefan Härtel

    Member of Supervisory Board

    • Tenure: 9.3yrs
    • Compensation: €82.00k
  • Georg Schulze-Ziehaus

    First Deputy Chairman of the Supervisory Board

    • Tenure: 4.3yrs
    • Compensation: €138.00k
  • Peter Berghöfer

    Member of Supervisory Board

    • Tenure: 9.3yrs
    • Compensation: €100.00k
  • Annette Beller

    Member of Supervisory Board

    • Tenure: 2.5yrs
    • Compensation: €172.00k

Company Information

RHÖN-KLINIKUM Aktiengesellschaft's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: RHÖN-KLINIKUM Aktiengesellschaft
  • Ticker: RKAG.Y
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: €1.466b
  • Listing Market Cap: €1.623b
  • Shares outstanding: 66.94m
  • Website: https://www.rhoen-klinikum-ag.com

Number of Employees


Location

  • RHÖN-KLINIKUM Aktiengesellschaft
  • Salzburger Leite 1
  • Bad Neustadt an der Saale
  • Bavaria
  • 97616
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RHKJ.FOTCPK (Pink Sheets LLC)YesBearer Ordinary SharesUSUSDJan 1992
RHKDB (Deutsche Boerse AG)YesBearer Ordinary SharesDEEURJan 1992
RHKXTRA (XETRA Trading Platform)YesBearer Ordinary SharesDEEURJan 1992
0NQHLSE (London Stock Exchange)YesBearer Ordinary SharesGBEURJan 1992
RHKDBATS-CHIXE (BATS 'Chi-X Europe')YesBearer Ordinary SharesGBEURJan 1992
RHKSWX (SIX Swiss Exchange)YesBearer Ordinary SharesCHCHFJan 1992
RHKWBAG (Wiener Boerse AG)YesBearer Ordinary SharesATEURJan 1992
RKAG.YOTCPK (Pink Sheets LLC)ADRUSUSDFeb 2010

Biography

RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services primarily in the areas of  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 00:08
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.